Seminars in Oncology
Volume 34 , Pages S12-S20 , April 2007

Hepatocellular Carcinoma (HCC): An Update

  • Philippe Rougier

      Affiliations

    • Service d’Hépato-gastroentérologie, Hopital Ambroise Paré, Boulogne, France.
    • Corresponding Author InformationAddress reprint requests to Prof Philippe Rougier, MD, Service d’Hépato-gastroentérologie, Hopital Ambroise Paré, 92100 Boulogne, France.
    • ,
  • Emmanuel Mitry

      Affiliations

    • Service d’Hépato-gastroentérologie, Hopital Ambroise Paré, Boulogne, France.
    • ,
  • Jean-Claude Barbare

      Affiliations

    • Service d’Hépato-gastroentérologie, Centre Hospitalier, Compiegne, France.
    • ,
  • Julien Taieb

      Affiliations

    • Service d’Hépato-gastroentérologie, Groupe Hospitalier Pitié Salpétrière, Paris, France.

References 

  1. El Sarrag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med. 2003;139:817–823
  2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917
  3. Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;26:1005–1014
  4. Mok TSK, Yeo W, Yu S, et al. An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results. J Clin Oncol. 2005;23:8041–8047
  5. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 2001;120:1763–1773
  6. Thomas MB, Abbruzzese JJ. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol. 2005;23:8093–8108
  7. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43:515–524
  8. Fujii T, Koshikawa K, Nomoto S, et al. Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J Hepatol. 2004;41:104–111
  9. Kurokawa Y, Matoba R, Takemasa I, et al. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol. 2004;41:284–291
  10. El-Serag HB, Siegel AB, Davila JA, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: A population-based study. J Hepatol. 2004;40:472–477
  11. Régimbeau JM, Farges O, Shen BY, et al. Is surgery for large hepatocellular carcinoma justified?. J Hepatol. 1999;31:1062–1068
  12. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699
  13. Figueras J, Jaurrieta E, Valls C, et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: Outcomes based on indicated treatment strategy. J Am Coll Surg. 2000;190:580–587
  14. Traissac L, Roudot-Thoraval F, Vanlemmens C, et al. Gain de survie apporté par la transplantation hépatique chez les malades transplantés pour carcinome hépatocellulaire. [abstr] Gastroenterol Clin Biol. 2001;25:A159
  15. Poon RT, Fan ST, Lo CM, et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: Implications for a strategy of salvage transplantation. Ann Surg. 2002;235:373–382
  16. Nkontchou G, Chevret S, Mohand D, et al. Petit carcinome hépatocellulaire isolé chez les patients atteints d’une cirrhose classée Child-Pugh A: Facteurs pronostiques chez 142 patients. [abstr] Gastroenterol Clin Biol. 2001;25:A18
  17. Llovet JM, Fuster J, Bruix J Barcelona Clinic Liver Cancer (BCLC) Group. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology. 1999;30:1434–1440
  18. Yao FY, Ferrel L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–1403
  19. Oldhafer KJ, Chavan A, Frühauf NR, et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: Marked tumor necrosis, but no survival benefit?. J Hepatol. 1998;29:953–959
  20. Sitruk V, Seror O, Grando-Lemaire V, et al. Traitement percutané du carcinome hépatocellulaire. Gastroenterol Clin Biol. 2003;27:381–390
  21. Llovet JM, Vilana R, Bru C, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology. 2001;33:1124–1129
  22. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–240
  23. Lin SM, Lin CJ, Lin CC, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤ 4 cm. Gastroenterology. 2004;127:1714–1723
  24. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122–130
  25. Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. [Erratum appears in: Gut 54:1508, 2005] Gut. 2005;54:1151–1156
  26. Lin CS, Jen YM, Chiu SY, et al. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol. 2006;36:212–217
  27. Daniele B, De Sio I, Izzo F, et al. Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma (A Cancer of the Liver Italian Program (CLIP 08) retrospective case-control study). J Clin Gastroenterol. 2003;36:63–67
  28. Huang GT, Lee PH, Tsang YM, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: A prospective study. Ann Surg. 2005;242:36–42
  29. Lu MD, Kuang M, Liang LJ, et al. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. Zhonghua Yi Xue Za Zhi. 2006;86:801–805
  30. Graziadei IW, Sandmueller H, Waldenberger P, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003;9:557–563
  31. Majno PE, Adam R, Bismuth H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg. 1997;226:688–703
  32. Oldhafer KJ, Chavan A, Fruhauf NR, et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: Marked tumor necrosis, but no survival benefit?. J Hepatol. 1998;29:953–959
  33. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl. 2005;11:767–775
  34. Mathurin P, Raynard B, Dharancy S, et al. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther. 2003;17:1247–1261
  35. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med. 1999;340:1046–1047
  36. Valla DC, Degos F. Chemoprevention of hepatocellular carcinoma in hepatitis C virus-related cirrhosis: First, eliminate the virus. J Hepatol. 2001;34:606–609
  37. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor –A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000;32:228–232
  38. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003;138:299–306
  39. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet. 2000;356:802–807
  40. Kuang M, Peng BG, Lu MD, et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004;10:1574–1579
  41. Lau WY, Leung TWT, Ho SKW, et al. Adjuvant intra-arterial iodine 131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial. Lancet. 1999;353:797–801
  42. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 1990;11:181–184
  43. Pelletier G, Ducreux M, Gay F, et al. Groupe CHC Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial. J Hepatol. 1998;29:129–134
  44. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995;332:1256–1261
  45. Lo CM, Tso WK, Liu CL, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–1171
  46. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet. 2002;359:1734–1739
  47. Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Radiology. 2002;224:47–54
  48. Llovet JM, Bruix J Barcelona-Clinic-Liver Cancer Group. Systematic review of randomized controlled trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429–442
  49. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461–469
  50. Chou YY, Cheng AL, Hsu HC. Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: Clinical correlation. J Gastroenterol Hepatol. 1997;12:569–575
  51. Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. Cancer. 1988;62:479–483
  52. Olweny C, Hakim J, Gudza I, et al. Quality of life-focused randomized clinical trial in the treatment of 113 hepatocellular carcinoma patients in Zimbabwe: A collaborative study. [abstr] Proc Am Soc Clin Oncol. 1999;18:575a
  53. van Eeden H, Falkson G, Burger W, et al. 5-Fluorouracil and leucovorin in hepatocellular carcinoma. Ann Oncol. 1992;3:404–405
  54. Bobbio-Pallavicini E, Porta C, Moroni M, et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: A phase II study. Eur J Cancer. 1997;33:1784–1788
  55. Bearz A, Sorio R, Tommasi G, et al. Oxaliplatin and 5-fluorouracil (5-FU) in hepatocarcinoma (HCC). [abstr] Proc Am Soc Clin Oncol. 2001;20:148b
  56. Fuloria J, Parikh PM, Prabhakaran P, et al. A multicenter, phase II trial of gemcitabine and cisplatin in unresectable hepatocellular carcinoma. [abstr] Proc Am Soc Clin Oncol. 2000;19:292a
  57. Tanioka H, Tsuji A, Morita S, et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res. 2003;23:1891–1897
  58. Taïeb JMT, Ducreux M, Bonyhay L, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma (HCC): Results of a phase II study. [abstr] J Clin Oncol. 2004;22:4086A
  59. Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: A randomized controlled trial. Hepatology. 1993;17:389–394
  60. Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 2000;31:54–58
  61. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97:1532–1538
  62. Butterfield LH. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology. 2004;127:S232–S241
  63. Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies (A review of immunological and clinical results). Ann Oncol. 2005;16:847–862
  64. Taieb J, Chaput N, Schartz N, et al. Chemoimmunotherapy of tumors: Cyclophosphamide synergizes with exosome based vaccines. J Immunol. 2006;176:2722–2729
  65. Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med. 2006;12:214–219
  66. Grimaldi C, Bleiberg H, Gay F, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: Results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol. 1998;16:411–417
  67. Chow PK, Tai BC, Tan CK, et al. Asia-Pacific Hepatocellular Carcinoma Trials Group High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology. 2002;36:1221–1226
  68. Barbare JC, Bouche O, Bonnetain F, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol. 2005;23:4338–4346
  69. Blaker M, Schmitz M, Gocht A, et al. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol. 2004;41:112–118
  70. Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: A randomised controlled study. Gut. 1998;42:442–447
  71. Yuen MF, Poon RT, Lai CL, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology. 2002;36:687–691
  72. Allgaier HP, Becker G, Olschewski M, et al. Octreotide treatment in patients with advanced hepatocellular carcinoma: First results of the randomised placebo-controlled double-blind HECTOR trial. [abstr] Hepatology. 2003;38:760A
  73. Barbare JC, Bouché O, Bonnetain F, et al. Résultats de l’essai multicentrique randomisé en double aveugle octréotide-retard versus placebo pour le traitement palliatif du carcinome hépatocellulaire: Étude CHOC FFCD-ANGH 2001-01. Gastroenterol Clin Biol. 2005;29:A88
  74. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology. 2002;49:1245–1250
  75. The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;31:840–845
  76. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma (Conclusions of the Barcelona-2000 EASL Conference). J Hepatol. 2001;35:421–430
  77. Ganne-Carrié N, Mohand D, N’Kontchou G, et al. Diagnostic et traitement du carcinome hépatocellulaire chez les malades atteints de cirrhose. Gastroenterol Clin Biol. 2002;26:73–77
  78. Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: Intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med. 1994;35:1782–1787
  79. Abou-Alfa GK. Current and novel therapeutics for hepatocellular carcinoma. In:  Perry MC editors. American Society of Clinical Oncology, Educational Book. 2004;p. 192–19740th Annual Meeting. Alexandria, VA
  80. Hisaka T, Yano H, Haramaki M, et al. Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: Relationship to cell proliferation. Int J Oncol. 1999;14:453–460
  81. Matsuo M, Sakurai H, Saiki I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther. 2003;2:557–561
  82. Zhu AX, Blaszkowsky L, Enzinger PC, et al. Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma. 2006;ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January (abstr 197)
  83. Miura H, Miyazaki T, Kuroda M, et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol. 1997;27:854–861
  84. Torimura T, Sata M, Ueno T, et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol. 1998;29:986–991
  85. Poon RT, Ng IO, Lau C, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: A prospective study. Ann Surg. 2001;233:227–235
  86. Schwartz JD, Schwartz M, Leher D, et al. Bevacizumab in hepatocellular carcinoma inpatients without metastasis and without invasion of the portal vein. [abstr] J Clin Oncol. 2005;23:4122A
  87. Zhu AX, Sahani D, Norden-Zfoni N, et al. A phase II study of gemcitabine, oxaliplatin in combination with bevacizumab in hepatocellular carcinoma in patients with hepatocellular carcinoma. [abstr] J Clin Oncol. 2005;23:4120A
  88. Ito Y, Takeda T, Sakon M, et al. Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology. 2000;59:68–74
  89. Hegewisch-Becker S, Sterneck M, Schubert U, et al. Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC). [abstr] J Clin Oncol. 2004;23:4089A
  90. Shah MA, Kortmansky J, Gonen M, et al. Mature results of a phase I study of irinotecan (CPT) and flavopiridol (F): A clinically and biologically active regimen. [abstr] Proc Am Soc Clin Oncol. 2003;22:1051A
  91. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma (A randomized controlled trial). Br J Cancer. 2001;84:886–891

PII: S0093-7754(07)00024-3

doi: 10.1053/j.seminoncol.2007.01.007

Seminars in Oncology
Volume 34 , Pages S12-S20 , April 2007

Article Tools